The drug, known as Breo Ellipta in the US, has already disappointed in one pivotal study. The Summit trial, published 12 months ago, showed the drug failed to cut the risk of death in COPD ...

ICER has published the research protocol (PDF) for the evaluation of Breo Ellipta ... fixed-dose generic alternatives or open generic combinations in patients with moderate to severe COPD.

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Therefore, the differences between treatments observed in the present study can be reasonably attributed to NAC and its dosage. In this study, patients with at least two exacerbations of COPD in ...

Pulmonary fibrosis is a disease where there is scarring of the lungs—called fibrosis—which makes it difficult to breathe. This is because the scarring causes the tissues in the lungs to get thick and ...

Introduction Novel therapies for pulmonary hypertension (PH) have improved survival and slowed disease progression. However, patients still present with symptoms of exertional dyspnoea and fatigue, ...

Always speak with a healthcare provider before taking a supplement to ensure that the ingredients and dosage are appropriate for your individual needs. Age, sex, and pregnancy status determine how ...